What is Structure?
Structure Therapeutics operates as a science-driven, clinical-stage biopharmaceutical organization dedicated to addressing significant unmet medical needs in chronic metabolic and cardiopulmonary diseases. The company distinguishes itself through a next-generation, structure-based drug discovery platform that targets G-protein-coupled receptors (GPCRs). By prioritizing the development of oral small-molecule compounds over traditional biologic or peptide-based treatments, Structure Therapeutics aims to enhance patient accessibility and treatment scalability. This strategic focus on oral delivery mechanisms positions the company as a potential disruptor in therapeutic areas that have historically relied on complex, injectable interventions.
How much funding has Structure raised?
Structure has raised a total of $320M across 3 funding rounds:
Series A
$26M
Series B
$133M
Stock Offering
$161M
Series A (2020): $26M, investors not publicly disclosed
Series B (2022): $133M led by Piper Heartland Healthcare Capital and Deep Track Capital
Stock Issuance/Offering (2023): $161M, investors not publicly disclosed
Key Investors in Structure
Deep Track Capital
Deep Track Capital is an investment firm located in Greenwich, Connecticut, that specializes in the life sciences industry, focusing exclusively on biotechnology investments.
Piper Heartland Healthcare Capital
A specialized investment group focused on providing growth capital to healthcare and life sciences companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Structure?
With the recent influx of capital, Structure Therapeutics is well-positioned to advance its lead candidates through critical clinical trial phases. The strategic deployment of these funds will likely prioritize the expansion of its proprietary pipeline and the optimization of its GPCR-targeting platform. As the company matures, the focus will shift toward demonstrating the efficacy and safety of its oral small-molecule portfolio in human trials, a pivotal step for commercial viability. Investors and industry stakeholders will be monitoring the company's ability to translate its structure-based discovery successes into tangible clinical outcomes, which will be essential for long-term value creation in the competitive biopharmaceutical landscape.
See full Structure company page
